Literature DB >> 3099912

Persistent HIV antigenaemia and decline of HIV core antibodies associated with transition to AIDS.

J M Lange, D A Paul, H G Huisman, F de Wolf, H van den Berg, R A Coutinho, S A Danner, J van der Noordaa, J Goudsmit.   

Abstract

Sequential serum samples from 13 homosexual men who seroconverted for antibodies to human immunodeficiency virus (HIV) were tested for HIV antigen. In one of these men, who developed the acquired immune deficiency syndrome (AIDS), HIV antigenaemia preceded the onset of AIDS by more than a year and persisted throughout the course of the disease. This antigenaemia was accompanied by the disappearance of IgG antibody reactivity to the major HIV core protein p24. In none of the 12 others, who all remained without serious disease, were serum concentrations of HIV antigen detected, except on one occasion in one man. All their serum samples showed strong IgG antibody reactivity to p24. Nine children who were infected with HIV in 1981 by plasma transfusion from a single donor were also followed up for HIV antigenaemia. HIV antigen was almost constantly present in the serum (26 of 28 samples) of five children who developed AIDS related complex or AIDS and less often in the serum (four of 10 samples) of four children who remained free of symptoms. The two children who developed AIDS showed a virtual absence of antibody reactivity to p24. These results indicate that increased HIV gene expression is a contributing factor to the development of AIDS and also provide evidence for a switch from latent to active HIV infection.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3099912      PMCID: PMC1342236          DOI: 10.1136/bmj.293.6560.1459

Source DB:  PubMed          Journal:  Br Med J (Clin Res Ed)        ISSN: 0267-0623


  18 in total

1.  Characterization of highly immunogenic p66/p51 as the reverse transcriptase of HTLV-III/LAV.

Authors:  F di Marzo Veronese; T D Copeland; A L DeVico; R Rahman; S Oroszlan; R C Gallo; M G Sarngadharan
Journal:  Science       Date:  1986-03-14       Impact factor: 47.728

2.  Induction of HTLV-III/LAV from a nonvirus-producing T-cell line: implications for latency.

Authors:  T Folks; D M Powell; M M Lightfoote; S Benn; M A Martin; A S Fauci
Journal:  Science       Date:  1986-02-07       Impact factor: 47.728

3.  Viral envelope protein of HTLV-III is the major target antigen for antibodies in hemophiliac patients.

Authors:  L Kitchen; G Malone; S Orgad; F Barin; R Zaizov; B Ramot; E Gazit; J Kreiss; M Leal; I Wichmann
Journal:  J Infect Dis       Date:  1986-04       Impact factor: 5.226

4.  Long-term seropositivity for human T-lymphotropic virus type III in homosexual men without the acquired immunodeficiency syndrome: development of immunologic and clinical abnormalities. A longitudinal study.

Authors:  M Melbye; R J Biggar; P Ebbesen; C Neuland; J J Goedert; V Faber; I Lorenzen; P Skinhøj; R C Gallo; W A Blattner
Journal:  Ann Intern Med       Date:  1986-04       Impact factor: 25.391

5.  Introduction of lymphadenopathy associated virus or human T lymphotropic virus (LAV/HTLV-III) into the male homosexual community in Amsterdam.

Authors:  R A Coutinho; W J Krone; L Smit; P Albrecht-van Lent; J van der Noordaa; W Schaesberg; J Goudsmit
Journal:  Genitourin Med       Date:  1986-02

6.  HTLV-III/LAV infection in nine children infected by a single plasma donor: clinical outcome and recognition patterns of viral proteins.

Authors:  J M Lange; H van den Berg; L J Dooren; J M Vossen; W Kuis; J Goudsmit
Journal:  J Infect Dis       Date:  1986-07       Impact factor: 5.226

7.  Recombinant polypeptide from the endonuclease region of the acquired immune deficiency syndrome retrovirus polymerase (pol) gene detects serum antibodies in most infected individuals.

Authors:  K S Steimer; K W Higgins; M A Powers; J C Stephans; A Gyenes; C George-Nascimento; P A Luciw; P J Barr; R A Hallewell; R Sanchez-Pescador
Journal:  J Virol       Date:  1986-04       Impact factor: 5.103

8.  Isolation of HTLV-III from cerebrospinal fluid and neural tissues of patients with neurologic syndromes related to the acquired immunodeficiency syndrome.

Authors:  D D Ho; T R Rota; R T Schooley; J C Kaplan; J D Allan; J E Groopman; L Resnick; D Felsenstein; C A Andrews; M S Hirsch
Journal:  N Engl J Med       Date:  1985-12-12       Impact factor: 91.245

9.  Efficacy of a heat inactivated hepatitis B vaccine in male homosexuals: outcome of a placebo controlled double blind trial.

Authors:  R A Coutinho; N Lelie; P Albrecht-Van Lent; E E Reerink-Brongers; L Stoutjesdijk; P Dees; J Nivard; J Huisman; H W Reesink
Journal:  Br Med J (Clin Res Ed)       Date:  1983-04-23

10.  Expression of human immunodeficiency virus antigen (HIV-Ag) in serum and cerebrospinal fluid during acute and chronic infection.

Authors:  J Goudsmit; F de Wolf; D A Paul; L G Epstein; J M Lange; W J Krone; H Speelman; E C Wolters; J Van der Noordaa; J M Oleske
Journal:  Lancet       Date:  1986-07-26       Impact factor: 79.321

View more
  78 in total

Review 1.  Frequency, causes, and new challenges of indeterminate results in Western blot confirmatory testing for antibodies to human immunodeficiency virus.

Authors:  Ming Guan
Journal:  Clin Vaccine Immunol       Date:  2007-04-04

Review 2.  Clinical, virological and immunological features of primary HIV-1 infection.

Authors:  M D de Jong; H J Hulsebosch; J M Lange
Journal:  Genitourin Med       Date:  1991-10

Review 3.  B cell responses to HIV and the development of human monoclonal antibodies.

Authors:  J E Boyd; K James
Journal:  Clin Exp Immunol       Date:  1992-05       Impact factor: 4.330

4.  Actuarial rate of clinical and biological progression in a cohort of 250 HIV-1-seropositive subjects. Laennec HIV Study Group.

Authors:  A Venet; J M Tourani; K Beldjord; D Eme; P Even; J M Andrieu
Journal:  Clin Exp Immunol       Date:  1990-05       Impact factor: 4.330

5.  Natural history of HIV-infection in hemophiliacs: clinical, immunological, and virological findings.

Authors:  T Kamradt; D Niese; K E Schneweis; H H Brackmann; B Kamps; B van Loo; U Hammerstein
Journal:  Klin Wochenschr       Date:  1989-10-17

6.  Biological significance of the antibody response to HIV antigens expressed on the cell surface.

Authors:  J Goudsmit; K Ljunggren; L Smit; M Jondal; E M Fenyö; M Jonda
Journal:  Arch Virol       Date:  1988       Impact factor: 2.574

7.  Analysis of oligoclonal antibody bands against individual HIV structural proteins in the CSF of patients infected with HIV.

Authors:  R Kaiser; R Dörries; W Lüer; S Poser; H D Pohle; K Felgenhauer; V ter Meulen
Journal:  J Neurol       Date:  1989-03       Impact factor: 4.849

8.  Patterns of antigenaemia and antibody response in patients infected with human immunodeficiency virus (HIV) according to clinical state.

Authors:  M C Re; G Furlini; M La Placa
Journal:  J Clin Pathol       Date:  1989-03       Impact factor: 3.411

9.  Declining incidence of AIDS dementia complex after introduction of zidovudine treatment.

Authors:  P Portegies; J de Gans; J M Lange; M M Derix; H Speelman; M Bakker; S A Danner; J Goudsmit
Journal:  BMJ       Date:  1989-09-30

10.  Cell-mediated immunity to HIV-1 in Walter Reed stages 1-6 individuals: correlation with virus burden.

Authors:  R J Trauger; W K Giermakowska; F Ferre; P C Duffy; M R Wallace; D E Lewis; H J Beecham; K G Burnett; F C Jensen; D J Carlo
Journal:  Immunology       Date:  1993-04       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.